{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Persistence and Adherence to 5-ASA Therapy for UC in Canada: Relevant Data from the Real-world Setting - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"R8XhLlZdyR\"><a href=\"https:\/\/themedicalxchange.com\/en\/2010\/10\/15\/the-american-college-of-gastroenterology-acg-2010\/\">Persistence and Adherence to 5-ASA Therapy for UC in Canada: Relevant Data from the Real-world Setting<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2010\/10\/15\/the-american-college-of-gastroenterology-acg-2010\/embed\/#?secret=R8XhLlZdyR\" width=\"600\" height=\"338\" title=\"&#8220;Persistence and Adherence to 5-ASA Therapy for UC in Canada: Relevant Data from the Real-world Setting&#8221; &#8212; The Medical Xchange\" data-secret=\"R8XhLlZdyR\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2010\/10\/ACG_graph1_en.png","thumbnail_width":962,"thumbnail_height":722,"description":"San Antonio \u2013 New claims data in Canada have revealed that adherence to 5-aminosalicylic acid (5-ASA) among patients with ulcerative colitis (UC) differs significantly among available formulations. These data have important public health implications because adherence to therapy is the single most important defense against relapse and complications of UC. Moreover, less well tolerated and generally more expensive immunomodulators and biologics follow in patients not controlled on 5-ASA, which is the guideline-defined first-line treatment for mild-to-moderate UC. Although multicentre trials with some of the available delayed-release 5-ASA agents have demonstrated that this form of therapy is effective for both acute healing and maintenance, this is clearly dependent on adequate adherence. The Canadian data suggest that high rates of avoidable relapses, incurring increased rates of hospitalization, surgery, and other adverse outcomes that raise cost of care, are being generated by suboptimal rates of 5-ASA adherence overall."}